CVS Caremark, which manages drug benefits for more than 40 million individuals, is granting preferred access to three Bioventus treatments for pain caused by knee osteoarthritis, according to a Nov. 10 announcement.
Beginning Jan. 1, 2021, Bioventus' Durolane, Gelsyn-3 and Supartz FX will be included among the four preferred knee osteoarthritis treatment options on the formulary for CVS Caremark members.
Durolane is a single-injection hyaluronic acid-based joint-fluid treatment for patients. Gelsyn-3 is a hyaluronic acid-based joint-fluid treatment requiring three injections, and Supartz is a five-injection hyaluronic acid-based joint-fluid treatment.